Identifying genetic alterations in poorly differentiated thyroid cancer: a rewarding pursuit.
作者信息
Xing Mingzhao
出版信息
J Clin Endocrinol Metab. 2009 Dec;94(12):4661-4. doi: 10.1210/jc.2009-2147.
Abstract
摘要
相似文献
1
Identifying genetic alterations in poorly differentiated thyroid cancer: a rewarding pursuit.鉴别低分化甲状腺癌中的基因改变：一项有意义的探索。
J Clin Endocrinol Metab. 2009 Dec;94(12):4661-4. doi: 10.1210/jc.2009-2147.
2
Genetic alterations in differentiated thyroid cancers.分化型甲状腺癌中的基因改变。
Endocr Metab Immune Disord Drug Targets. 2009 Sep;9(3):257-68. doi: 10.2174/187153009789044338. Epub 2009 Sep 1.
3
Pediatric Thyroid Cancer.小儿甲状腺癌
Adv Pediatr. 2017 Aug;64(1):171-190. doi: 10.1016/j.yapd.2017.03.007.
4
TWIST1 plays a pleiotropic role in determining the anaplastic thyroid cancer phenotype.TWIST1 在决定间变性甲状腺癌表型方面起着多效作用。
J Clin Endocrinol Metab. 2011 May;96(5):E772-81. doi: 10.1210/jc.2010-1182. Epub 2011 Mar 9.
5
BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic.BRAFV600E 突变在捷克共和国一系列大型甲状腺乳头癌发病机制中的作用。
J Endocrinol Invest. 2010 May;33(5):318-24. doi: 10.1007/BF03346593. Epub 2009 Dec 4.
6
RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact.RAS 突变是低分化甲状腺癌中主要的分子改变，并具有预后影响。
J Clin Endocrinol Metab. 2009 Dec;94(12):4735-41. doi: 10.1210/jc.2009-1233. Epub 2009 Oct 16.
7
Cribriform-Morular Variant of Papillary Thyroid Carcinoma With Poorly Differentiated Features: A Case Report With Immunohistochemical and Molecular Genetic Analysis.具有低分化特征的甲状腺乳头状癌筛状-桑葚状变体：一例免疫组织化学和分子遗传学分析的病例报告
Int J Surg Pathol. 2019 May;27(3):294-304. doi: 10.1177/1066896918796946. Epub 2018 Sep 3.
8
Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.丙酮酸激酶 M2 的异常过表达与甲状腺乳头状癌中具有侵袭性肿瘤特征和 BRAF 突变相关。
J Clin Endocrinol Metab. 2013 Sep;98(9):E1524-33. doi: 10.1210/jc.2012-4258. Epub 2013 Jul 11.
9
Follicular thyroid carcinoma with rhabdoid phenotype.具有横纹肌样表型的滤泡性甲状腺癌。
Virchows Arch. 1999 Aug;435(2):133-6. doi: 10.1007/s004280050410.
10
Cell adhesion-related gene somatic mutations are enriched in aggressive papillary thyroid microcarcinomas.细胞黏附相关基因体细胞突变在侵袭性甲状腺微小乳头状癌中富集。
J Transl Med. 2018 Oct 1;16(1):269. doi: 10.1186/s12967-018-1642-0.
引用本文的文献
1
Combinatorial Therapies in Thyroid Cancer: An Overview of Preclinical and Clinical Progresses.甲状腺癌的联合治疗：临床前和临床进展概述。
Cells. 2020 Mar 30;9(4):830. doi: 10.3390/cells9040830.
2
Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.HNHA 和仑伐替尼通过抑制癌症干细胞 EMT 介导的耐药性发挥抗癌作用。
Neoplasia. 2018 Feb;20(2):197-206. doi: 10.1016/j.neo.2017.12.003. Epub 2018 Jan 12.
3
Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications.甲状腺癌中的信号通路及其治疗意义。
J Clin Med Res. 2016 Apr;8(4):284-96. doi: 10.14740/jocmr2480w. Epub 2016 Feb 27.
4
Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas.未分化和低分化甲状腺癌中的基因改变。
Curr Genomics. 2011 Dec;12(8):609-17. doi: 10.2174/138920211798120853.
5
The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.Akt 特异性抑制剂 MK2206 选择性地抑制携带可激活 PI3K/Akt 通路的突变的甲状腺癌细胞。
J Clin Endocrinol Metab. 2011 Apr;96(4):E577-85. doi: 10.1210/jc.2010-2644. Epub 2011 Feb 2.
本文引用的文献
1
RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact.RAS 突变是低分化甲状腺癌中主要的分子改变，并具有预后影响。
J Clin Endocrinol Metab. 2009 Dec;94(12):4735-41. doi: 10.1210/jc.2009-1233. Epub 2009 Oct 16.
2
Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.磷脂酰肌醇3-激酶/蛋白激酶B信号通路中的基因改变赋予甲状腺癌细胞对蛋白激酶B和雷帕霉素哺乳动物靶点治疗性靶向的敏感性。
Cancer Res. 2009 Sep 15;69(18):7311-9. doi: 10.1158/0008-5472.CAN-09-1077. Epub 2009 Aug 25.
3
Genetic-targeted therapy of thyroid cancer: a real promise.甲状腺癌的基因靶向治疗：一个真正的前景。
Thyroid. 2009 Aug;19(8):805-9. doi: 10.1089/thy.2009.1583.
4
Recent advances in molecular biology of thyroid cancer and their clinical implications.甲状腺癌分子生物学的最新进展及其临床意义。
Otolaryngol Clin North Am. 2008 Dec;41(6):1135-46, ix. doi: 10.1016/j.otc.2008.07.001.
5
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.BRAF（V600E）突变与甲状腺乳头状癌患者的预后：一项15年中位随访研究
J Clin Endocrinol Metab. 2008 Oct;93(10):3943-9. doi: 10.1210/jc.2008-0607. Epub 2008 Aug 5.
6
Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia.甲状腺肿瘤中磷脂酰肌醇3激酶途径的失调。
Endocrinol Metab Clin North Am. 2008 Jun;37(2):375-87, viii-ix. doi: 10.1016/j.ecl.2008.01.001.
7
Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.间变性甲状腺癌和滤泡状甲状腺癌中受体酪氨酸激酶、磷脂酰肌醇3激酶/蛋白激酶B及丝裂原活化蛋白激酶信号通路中高度普遍的基因改变
J Clin Endocrinol Metab. 2008 Aug;93(8):3106-16. doi: 10.1210/jc.2008-0273. Epub 2008 May 20.
8
BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.与其他基因事件相关的BRAF突变可识别侵袭性乳头状甲状腺癌的一个亚组。
Clin Endocrinol (Oxf). 2008 Apr;68(4):618-34. doi: 10.1111/j.1365-2265.2007.03077.x. Epub 2007 Dec 5.
9
Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.中东人群中伴有PIK3CA改变的甲状腺乳头状癌的临床病理分析
J Clin Endocrinol Metab. 2008 Feb;93(2):611-8. doi: 10.1210/jc.2007-1717. Epub 2007 Nov 13.
10
BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.甲状腺乳头状癌中的BRAF突变：致病作用、分子基础及临床意义。
Endocr Rev. 2007 Dec;28(7):742-62. doi: 10.1210/er.2007-0007. Epub 2007 Oct 16.
Zotero 插件